Machine Learning for Early Detection of Cognitive Decline in Parkinson’s Disease Using Multimodal Biomarker and Clinical Data
Authors:
- Raziyeh MohammadiRMRaziyeh Mohammadi
- Samuel Y. E. NgSNSamuel Y. E. Ng
- Jayne Y. TanJTJayne Y. Tan
- Adeline S. L. NgANAdeline S. L. Ng
- Xiao DengXDXiao Deng
- Xinyi ChoiXCXinyi Choi
- Dede L. HengDHDede L. Heng
- Shermyn NeoSNShermyn Neo
- Zheyu XuZXZheyu Xu
- Kay-Yaw TayKTKay-Yaw Tay
- Wing-Lok AuWAWing-Lok Au
- Eng-King TanEng-King Tan
Open Access
- 3 December 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2758
Abstract
Background: Parkinson’s disease (PD) is the second most common neurodegenerative disease, primarily affecting the middle-aged to elderly population. Among its nonmotor symptoms, cognitive decline (CD) is a precursor to dementia and represents a critical target for early risk assessment and diagnosis. Accurate CD prediction is crucial for timely intervention and tailored management of at-risk patients. This study used machine learning (ML) techniques to predict the CD risk over five-year in early-stage PD. Methods: Data from the Early Parkinson’s Disease Longitudinal Singapore (2014 to 2018) was used to predict CD defined as a one-unit annual decrease or a one-unit decline in Montreal Cognitive Assessment over two consecutive years. Four ML methods—AutoScore, Random Forest, K-Nearest Neighbors and Neural Network—were applied using baseline demographics, clinical assessments and blood biomarkers. Results: Variable selection identified key predictors of CD, including education year, diastolic lying blood pressure, diastolic standing blood pressure, systolic lying blood pressure, Hoehn and Yahr scale, body mass index, phosphorylated tau at threonine 181, total tau, Neurofilament light chain and suppression of tumorigenicity 2. Random Forest was the most effective, achieving an AUC of 0.93 (95% CI: 0.89, 0.97), using 10-fold cross-validation. Conclusions: Here, we demonstrate that ML-based models can identify early-stage PD patients at high risk for CD, supporting targeted interventions and improved PD management.Keywords
All Related Versions
Funding Information
- Singapore Ministry of Health’s National Medical Research Council (MOH-OFLCG18May-0002, MOH-CSAINV21-0005, CNIG22jul-0004)
This publication has 68 references indexed in Scilit:
- Association between the blood pressure variability and cognitive decline in Parkinson's diseaseBrain and Behavior, 2023
- Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's DiseaseAnnals of Neurology, 2022
- Modifiable Comorbidities Associated with Cognitive Decline in Parkinson's DiseaseMovement Disorders Clinical Practice, 2020
- CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive TrajectoriesMovement Disorders, 2020
- The influence of vascular risk factors on cognitive function in early Parkinson's diseaseInternational Journal of Geriatric Psychiatry, 2017
- Plasma epidermal growth factor levels predict cognitive decline in Parkinson diseaseAnnals of Neurology, 2010
- Catechol‐O‐methyltransferase val158met and cognitive function in Parkinson's diseaseMovement Disorders, 2010
- Nonmotor manifestations of Parkinson's diseaseAnnals of Neurology, 2009
- The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 yearsMovement Disorders, 2008
- Index for rating diagnostic testsCancer, 1950